All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Why could IMGN632 be an important treatment option for AML?
Bookmark this article
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked: Why could IMGN632, a novel CD123-targeting antibody-drug conjugate, be an important treatment option for acute myeloid leukemia?
Eunice Wang discusses the results from the phase Ib study that explored the potent IMGN632 antibody-drug conjugate in patients with AML. She discusses the toxicity and safety profile of the agent and states the recommended dose. She also talks about the efficacy of this antibody-drug conjugate in the high-risk patient population.
Why could IMGN632 be an important treatment option for AML?
Your opinion matters
29 votes - 41 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox